ArQule, Inc. (NASDAQ:ARQL) Weekly Ratings as of Apr 17, 2018

April 17, 2018 - By Robert Reynolds

ArQule, Inc. (NASDAQ:ARQL) Corporate Logo

ArQule, Inc. (NASDAQ:ARQL) Ratings Coverage

Total analysts of 5 have positions in Arqule (NASDAQ:ARQL) as follows: 5 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since December 14, 2017 according to StockzIntelligence Inc Arqule has 5 analyst reports. In Monday, February 12 report B. Riley & Co maintained the stock with “Buy” rating. On Thursday, December 14 the rating was upgraded by Needham to “Buy”. On Thursday, April 5 the company was upgraded by Leerink Swann. In Friday, February 2 report FBR Capital initiated the stock with “Buy” rating. Listed here are ArQule, Inc. (NASDAQ:ARQL) PTs and latest ratings.

05/04/2018 Broker: Leerink Swann Rating: Buy New Target: $5.0000 Upgrade
22/02/2018 Broker: Roth Capital Rating: Buy New Target: $5 Initiates Coverage On
12/02/2018 Broker: B. Riley & Co Rating: Buy Old Target: $3 New Target: $3.5 Maintain
02/02/2018 Broker: FBR Capital Rating: Buy New Target: $3.0 Initiate
14/12/2017 Broker: Needham Old Rating: Hold New Rating: Buy Upgrade

On during the last trading session the stock increased $0.15 or 5.56%, reaching $2.85.ArQule, Inc. has volume of 271,249 shares. Since April 17, 2017 ARQL has risen 180.00% and is uptrending. The stock outperformed the S&P500 by 168.45%.

ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States.The firm is valued at $248.26 million. The Company’s lead product candidate is tivantinib , a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer.Last it reported negative earnings. The companyÂ’s clinical-stage products include ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor family Phase II clinical trial for patients with intrahepatic cholangiocarcinoma and in Phase Ib for multiple oncology indications; ARQ 092, an inhibitor of the AKT serine/threonine kinase in Phase I clinical trials for multiple oncology indications; ARQ 751, a next-generation inhibitor of AKT in Phase I clinical trial for solid tumors; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is Phase 1b clinical trial used as a promoter of NQo1-mediated programmed cancer cell death.

ArQule, Inc. (NASDAQ:ARQL) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.